Human drug hepatotoxicity: A contemporary clinical perspective

Expert Opinion on Drug Metabolism and Toxicology

Volumn 5, Issue 5, 2009, Pages 463-473

  Assis, David N ^a   Navarro, Victor J ^a  

^a THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

Author keywords

Causality assessment; DILI; DILIN; Drug hepatotoxicity; Early detection; RUCAM

Indexed keywords

ALLOPURINOL; AMFEBUTAMONE; AMIODARONE; ANABOLIC AGENT; AZATHIOPRINE; CAPTOPRIL; CHLORPROMAZINE; CLINDAMYCIN; CLOPIDOGREL; DICLOFENAC; ENALAPRIL; ERYTHROMYCIN; FLUCLOXACILLIN; FLUOXETINE; FOSINOPRIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; ISONIAZID; KETOCONAZOLE; LISINOPRIL; ORAL CONTRACEPTIVE AGENT; PARACETAMOL; PHENOTHIAZINE DERIVATIVE; TERBINAFINE; TETRACYCLINE; TRICYCLIC ANTIDEPRESSANT AGENT; TROGLITAZONE; UNINDEXED DRUG; VALPROIC ACID; VERAPAMIL;

CAUSAL ATTRIBUTION; CLINICAL FEATURE; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DRUG INDUCED LIVER INJURY; EARLY DIAGNOSIS; HUMAN; LIVER FUNCTION TEST; LIVER INJURY; LIVER TOXICITY; PHARMACOEPIDEMIOLOGY; REVIEW; RISK ASSESSMENT; RISK FACTOR;

ADVERSE DRUG REACTION REPORTING SYSTEMS; AGE FACTORS; CLINICAL TRIALS AS TOPIC; HUMANS; LIVER DISEASES; LIVER FUNCTION TESTS; PHARMACEUTICAL PREPARATIONS; POLYPHARMACY; RISK FACTORS; UNITED STATES;

EID: 67649383640     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425250902927386     Document Type: Review

References (83)

1. Ostapowicz G, Fontana RJ, Schiødt FV, et al. U.S. Acute Liver Failure Study Group. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002;137:947-954
2. Larrey D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Semin Liv Dis 2002;22:145-156 (Pubitemid 34496468)
3. Sgro C, Clinard F, Ouazir K, et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 2002;36:451-455 (Pubitemid 34810366)
4. Lee WM. Drug-induced hepatotoxicity. N Engl J Med 2003;349:474-485 • Comprehensive discussion of the various mechanisms of DILI. (Pubitemid 36910027)
5. Andrade RJ, Robles M, Fernandez-Castaner A, et al. Assessment of drug-induced hepatotoxicity in clinical practice: a challenge for gastroenterologists. World J Gastroenterol 2007;13:329-340 (Pubitemid 46178965)
6. Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med 2006;354:731-739 •• Comprehensive discussion of the clinical approach to DILI. (Pubitemid 43247143)
7. Abboud G, Kaplowitz N. Drug-induced liver injury. Drug Saf 2007;30:277-294 (Pubitemid 46624528)
8. Elinav E, Pinsker G, Safadi R, et al. Association between consumption of Herbalife® nutritional supplements and acute hepatotoxicity. J Hepatol 2007;47:514-520 (Pubitemid 47331750)
9. Schoepfer AM, Engel A, Fattinger K, et al. Herbal does not mean innocuous: 10 cases of severe hepatotoxicity associated with dietary supplements from Herbalife® products. J Hepatol 2007;47:521-526 (Pubitemid 47331751)
10. Adachi M, Saito H, Kobayashi H, et al. Hepatic injury in 12 patients taking the herbal weight loss aids Chaso or Onshido. Ann Intern Med 2003;139:488-492 (Pubitemid 38124574)
11. Bonkovsky HL. Hepatotoxicity associated with supplements containing Chinese green tea (Camellia sinensis). Ann Intern Med 2006;144:68-71 (Pubitemid 46780727)
12. Neff GW, Reddy KR, Durazo FA, et al. Severe hepatotoxicity associated with the use of weight loss diet supplements containing ma huang or usnic acid. J Hepatol 2004;41:1062-1064 (Pubitemid 39575679)
13. Degott C, Feldmann G, Larrey D, et al. Drug-induced prolonged cholestasis in adults: a histological semiquantitiative study demonstrating progressive ductopenia. Hepatology 1992;15:244-251
14. Desmet VJ. Vanishing bile duct syndrome in drug-induced liver disease. J Hepatol 1997;26(Suppl 1):31-35 (Pubitemid 127777235)
15. Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. New York: Appleton-Century-Crofts, 1978
16. Goodman ZD. Drug hepatotoxicity. Clin Liv Dis 2002;6:381-397 (Pubitemid 34755898)
17. Chang CY, Schiano TD. Review article: drug hepatotoxicity. Alim Pharm Ther 2007;25:1135-1151 (Pubitemid 46650295)
18. Benichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. Hepatology 1990;11:272-276
19. Danan G, Benichou C. Causality assessment of adverse reactions to drugs - I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993;46:1323-1330 (Pubitemid 23333873)
20. Benichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs-II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol 1993;46:1331-1336 (Pubitemid 23333874)
21. Maria VA, Victorino RM. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology 1997;26:664-669 (Pubitemid 27392358)
22. Lucena MI, Camargo R, Andrade RJ, et al. Comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatology 2001;33:123-130 (Pubitemid 32016894)
23. Shapiro MA, Lewis JH. Causality assessment of drug-induced hepatotoxicity: promises and pitfalls. Clin Liver Dis 2007;11:477-505 • Comprehensive discussion of the current models for causality assessment in DILI. (Pubitemid 47302343)
24. Arimone Y, Begaud B, Miremont-Salame G, et al. Agreement of expert judgment in causality assessment of adverse drug reactions. Eur J Clin Pharmacol 2005;61:169-173 (Pubitemid 40768547)
25. Aithal GP, Rawlins MD, Day CP. Accuracy of hepatic adverse drug reaction reporting in one English health region. BMJ 1999;391:1541
26. Rochon J, Protiva P, Seeff LB, et al. Reliability of the roussel uclaf causality assessment method for assessing causality in drug-induced liver injury. Hepatology 2008;48:1175-1183
27. Brinker AD, Wassel RT, Lyndly J, et al. Telithromycin-associated hepatotoxicity: clinical spectrum and causality assessment of 42 cases. Hepatology 2009;49:250-257
28. Drug-induced liver injury network. Available from: http://dilin.dcri. duke.edu/ [Last accessed 1 February 2009]
29. Hoofnagle JH. Drug-induced liver injury network (DILIN). Hepatology 2004;40:773 • Initial description of the DILIN and its goals.
30. Fontana RJ, Watkins PB, Bonkovsky HL, et al. Drug-induced liver injury network (DILIN) prospective study. Drug Saf 2009;32:55-68
31. Fountain FF, Tolley E, Chrisman CR, et al. Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic. Chest 2005;128:116-123 (Pubitemid 40994462)
32. Kopanoff DE, Snider DE Jr, Caras GJ. Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study. Am Rev Respir Dis 1978;117:991-1001
33. Nolan CM, Goldberg SV, Buskin SE. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA 1999;281:1014-1018 (Pubitemid 29143893)
34. Gronhagen-Riska C, Hellstrom PE, Froseth B. Predisposing factors in hepatitis induced by isoniazid-rifampin treatment of tuberculosis. Am Rev Resp Dis 1978;118:461-466 (Pubitemid 9027187)
35. Dickinson DS, Bailey WC, Hirschowitz BI, et al. Risk factors for isoniazid (INH)-induced liver dysfunction. J Clin Gastroenterol 1981;3:271-279 (Pubitemid 11053230)
36. Ungo JR, Jones D, Ashkin D, et al. Antituberculous drug-induced hepatotoxicity. The role of hepatitis C virus and immunodeficiency virus. Am J Respir Crit Care Med 1998;157:1871-1876 (Pubitemid 28311273)
37. Lee WM, Senior JR. Recognizing drug-induced liver injury: current problems, possible solutions. Toxicol Pathol 2005;33:155-164 (Pubitemid 40216814)
38. Watkins PB. Idiosyncratic liver injury: challenges and approaches. Toxicol Pathol 2005;33:1-5 (Pubitemid 40216797)
39. Mitchell AA, Lacouture PG, Sheehan JE, et al. Adverse drug reactions in children leading to hospital admission. Pediatrics 1988;82:24-29 (Pubitemid 18164071)
40. Squires RH, Shneider BL, Bucuvalas J, et al. Acute liver failure in children: the first 348 patients in the pediatric acute liver failure study group. J Pediatr 2006;148:652-658 (Pubitemid 43792501)
41. Huang YS, Su WJ, Huang YH, et al. Genetic polymorphisms of manganese superoxide dismuatase, NAD(P)H:quinone oxidoreductase, glutathione S-transferase M1 and T1, and the susceptibility to drug-induced liver injury. J Hepatol 2007;47:128-134 (Pubitemid 46817689)
42. Vuilleumier N, Rossier MF, Chiappe A, et al. CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis. Eur J Clin Pharmacol 2006;62:423-429 (Pubitemid 44069498)
43. Lucena MI, Andrade RJ, Martinez C, et al. Glutathione S-transferase M1 and T1 null genotypes increase susceptibility to idiosyncratic drug-induced liver injury. Hepatology 2008;48:588-596
44. Tarantino G, Conca P, Basile V, et al. A prospective study of acute drug-induced liver injury in patients suffering from non-alcoholic fatty liver disease. Hepatol Res 2007;37:410-415 (Pubitemid 46915785)
45. Day CP. Nash-related liver failure: one hit too many? Am J Gastroenterol 2002;97:1872-1874
46. El-Serag HB, Everhart JE. Diabetes increases the risk of acute hepatic failure. Gastroenterology 2002;122:1822-1828 (Pubitemid 34651427)
47. Aranzabal L, Casado JL, Moya J, et al. Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis 2005;40:588-593 (Pubitemid 40270230)
48. Sulkowski MS, Thomas DL, Chaisson RE, et al. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000;283:74-80 (Pubitemid 30038386)
49. Lammert C, Einarsson S, Saha C, et al. Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. Hepatology 2008;47:2003-2009 (Pubitemid 351945567)
50. Senior JR. What is idiosyncratic hepatotoxicity? What is it not? Hepatology 2008;47:1813-1815
51. Weinshilboum R. Inheritance and drug response. N Engl J Med 2003;348:529-537 (Pubitemid 36159889)
52. Matzinger P. Tolerance, danger, and extended family. Annu Rev Immunol 1994;12:991-1045 (Pubitemid 24140436)
53. Donaldson PT, Bhatnagar P, Graham J, et al. Flucloxacillin-induced liver injury: the extended MHC 57.1 haplotype as a major risk factor. Hepatology 2008;48(Suppl):396A
54. Maria VA, Victorino RM. Diagnostic value of specific T cell reactivity to drugs in 95 cases of drug induced liver injury. Gut 1997;41:534-540 (Pubitemid 27448788)
55. Usui K, Oda Y, Kubota R, et al. Clinical application of the leukocyte migration test and new diagnostic criteria for identifying causative agents in patients with drug-induced livery injury. Hepatogastroenterology 2007;54:1752-1757 (Pubitemid 350068471)
56. Davern TJ, James LP, Hinson JA, et al. Measurement of serum acetaminophen-protein adducts in patients with acute liver failure. Gastroenterology 2006;130:687-694 (Pubitemid 43374519)
57. Fontana RJ. Acute liver failure including acetaminophen overdose. Med Clin N Am 2008;92:761-794 (Pubitemid 351822355)
58. Lecoeur S, Andre C, Beaune PH. Tienilic acid-induced autoimmune hepatitis: anti-liver and -kidney microsomal type 2 autoantibodies recognize a three-site conformational epitope on cytochrome P4502C9. Mol Pharmacol 1996;50:326-333 (Pubitemid 26265137)
59. Phillips KA, Veenstra DL, Oren E, et al. Potential role of pharmacogenomics in reducing adverse drug reactions - a systematic review. JAMA 2001;286:2270-2279 (Pubitemid 33063150)
60. Wilke RA, Lin DW, Roden DM, et al. Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nat Rev Drug Discov 2007;6:904-916 (Pubitemid 350042398)
61. Issa AM. Clinical applications of pharmacogenomics to adverse drug reactions. Expert Rev Clin Pharmacol 2008;1:251-260
62. Alfirevic A, Pirmohamed M. Adverse drug reactions and pharmacogenomics: recent advances. Personalized Med 2008;5:11-23
63. Mendrick DL, Daniels KK. Biomarkers of drug-induced adverse events. Expert Rev Clin Pharmacol 2008;1:81-91
64. Goldschlager N, Epstein NE, Naccarelli G, et al. Practical guidelines for clinicians who treat patients with amiodarone. Practice guidelines subcommittee; North American society of pacing and electrophysiology. Arch Intern Med 2000;160:1741-1748
65. Lewis JH, Ranard RC, Caruso A, et al. Amiodarone hepatotoxicity: prevalence and clinicopathologic correlations among 104 patients. Hepatology 1989;9:679-685 (Pubitemid 19123513)
66. CDC Core Curriculum on Tuberculosis (2000). Available from: http://www.cdc.gov/tb/pubs/corecurr/Chapter6/Chapter-6-Monitoring.htm [Last accessed 1 February 2009]
67. Graham DJ, Green L, Senior JR, et al. Troglitazone-induced liver failure: a case study. Am J Med 2003;114:299-306 (Pubitemid 36398076)
68. Graham DJ, Drinkard CR, Shatin D, et al. Liver enzyme monitoring in patients treated with troglitazone. JAMA 2001;286:831-833 (Pubitemid 33015577)
69. Nathwani RA, Kaplowitz N. Drug hepatotoxicity. Clin Liv Dis 2006;10:207-217 (Pubitemid 46107014)
70. Watkins PB, Seeff LB. Drug-induced liver injury: summary of a single topic clinical research conference. Hepatology 2006;43:618-631
71. Ahmad SR. Adverse drug event monitoring at the food and drug administration. J Gen Int Med 2003;18:57-60
72. Arnaiz JA, Carne X, Riba N, et al. The use of evidence in pharmacovigilance. Case reports as the reference source for drug withdrawals. Eur J Clin Pharmacol 2001;57:89-91 (Pubitemid 32391420)
73. Ray WA. Population-based studies of adverse drug effects. N Engl J Med 2003;349:1592-1594 (Pubitemid 37288566)
74. Hazell L, Shakir SAW. Under-reporting of adverse drug reactions: a systematic review. Drug Saf 2006;29:385-396 (Pubitemid 43752541)
75. Chalasani N, Fontana RJ, Bonkovksy HL, et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008;135:1924-1934
76. Eudra Vigilance. Available from: http://eudravigilance.emea.europa.eu/ human/index.asp [Last accessed 1 February 2009]
77. Uppsala Monitoring Centre. Available from: http://www.who-umc.org/ DynPage. aspx [Last accessed 1 February 2009]
78. FDA Guidance for Industry - Drug-Induced Liver Injury: premarketing clinical evaluation. Available from: http://www.fda.gov/Cder/guidance/7507dft. htm [Last accessed 11 February 2009]
79. Pfeffer MA, Keech A, Sacks FM, et al. Safety and tolerability of pravastatin in long-term clinical trials: prospective pravastatin pooling (PPP) project. Circulation 2002;105:2341-2346 (Pubitemid 34556383)
80. Tolman KG. The liver and lovastatin. Am J Cardiol 2002;89:1374-1380 (Pubitemid 34607777)
81. Chalsani N, Aljadhey H, Kesterton J, et al. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology 2004;126:1287-1292 (Pubitemid 38552793)
82. Lewis JH, Mortensen ME, Zweig S, et al. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: results of a prospective, randomized, double-blind, placebo-controlled multicenter trial. Hepatology 2007;46:1453-1463 (Pubitemid 350155527)
83. Russo MW, Galanko JA, Shrestha R, et al. Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl 2004;10:1018-1023 (Pubitemid 39232756)